Jason Coloma, Maze CEO
May 10, 2024 05:51 AM EDTUpdated 06:57 AM
Deals
R&D
Pharma

Af­ter FTC scruti­ny of Sanofi deal, Maze finds a new Pompe part­ner in Sh­iono­gi

Kyle LaHucik

Senior Reporter

Maze Ther­a­peu­tics has found a new buy­er for its Pompe dis­ease can­di­date, five months af­ter scruti­ny from the Fed­er­al Trade Com­mis­sion led Sanofi to back …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Sur­round­ed by AI bio gi­ants, tiny start­up Nabla Bio makes de no­vo an­ti­bod­ies look more like drugs 

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times